These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27265893)

  • 1. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
    Wysham C; Guerci B; D'Alessio D; Jia N; Botros FT
    Diabetes Obes Metab; 2016 Nov; 18(11):1138-1142. PubMed ID: 27265893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
    Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
    Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
    Araki E; Inagaki N; Tanizawa Y; Oura T; Takeuchi M; Imaoka T
    Diabetes Obes Metab; 2015 Oct; 17(10):994-1002. PubMed ID: 26179754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
    Pantalone KM; Patel H; Yu M; Fernández Landó L
    Diabetes Obes Metab; 2018 Jun; 20(6):1461-1469. PubMed ID: 29430801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
    Umpierrez GE; Pantalone KM; Kwan AY; Zimmermann AG; Zhang N; Fernández Landó L
    Diabetes Obes Metab; 2016 Jun; 18(6):615-22. PubMed ID: 26969812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
    Frias JP; Wynne AG; Matyjaszek-Matuszek B; Bartaskova D; Cox DA; Woodward B; Li YG; Tham LS; Milicevic Z
    Diabetes Obes Metab; 2019 Sep; 21(9):2048-2057. PubMed ID: 31050143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
    Umpierrez G; Tofé Povedano S; Pérez Manghi F; Shurzinske L; Pechtner V
    Diabetes Care; 2014 Aug; 37(8):2168-76. PubMed ID: 24842985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
    Chen YH; Huang CN; Cho YM; Li P; Gu L; Wang F; Yang J; Wang WQ
    Diabetes Obes Metab; 2018 Sep; 20(9):2121-2130. PubMed ID: 29708650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
    Morioka T; Takeuchi M; Ozeki A; Emoto M
    Diabetes Obes Metab; 2024 Aug; 26(8):3167-3175. PubMed ID: 38715179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
    Weinstock RS; Guerci B; Umpierrez G; Nauck MA; Skrivanek Z; Milicevic Z
    Diabetes Obes Metab; 2015 Sep; 17(9):849-58. PubMed ID: 25912221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
    Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
    Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Giorgino F; Benroubi M; Sun JH; Zimmermann AG; Pechtner V
    Diabetes Care; 2015 Dec; 38(12):2241-9. PubMed ID: 26089386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
    Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
    Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.